Eversept Partners, LP Dyne Therapeutics, Inc. Transaction History
Eversept Partners, LP
- $1.29 Billion
- Q3 2025
A detailed history of Eversept Partners, LP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Eversept Partners, LP holds 10,000 shares of DYN stock, worth $188,400. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$188,400% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
227Shares Held
148MCall Options Held
184KPut Options Held
243K-
Janus Henderson Group PLC London, X014.7MShares$278 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.76MShares$184 Million0.0% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$172 Million26.07% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$139 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$103 Million13.81% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $975M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...